Welcome to our dedicated page for Sanara MedTech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Sanara MedTech Inc. has agreed to be acquired by MiMedx Group, Inc. in a cash-and-stock transaction valued at $35 per Sanara share, implying an enterprise value of approximately $350 million.
Sanara stockholders will receive $33.00 in cash plus 0.4735 shares of MiMedx common stock for each Sanara share. The companies describe the combination as creating a leading regenerative medicine business focused on surgical subspecialties. Sanara notes it recently exceeded $100 million in net revenue for the first time and has improved profitability. Both companies expect the transaction to close by the end of the year, subject to regulatory approvals, Sanara stockholder approval and other customary conditions, and to operate as separate entities until closing.
Sanara MedTech Inc. has entered into a definitive agreement to be acquired by MiMedx Group, Inc. in a cash and stock transaction valuing Sanara at approximately $350 million. Sanara shareholders are expected to receive $33.00 in cash plus 0.4735 shares of MiMedx common stock for each Sanara share.
The combination is described as creating a leading regenerative medicine company focused on surgical subspecialties, extending MiMedx’s reach beyond soft tissue into areas such as musculoskeletal applications. Closing is expected by year-end, subject to Sanara stockholder approval, required regulatory approvals and other customary conditions; until then, the companies will operate as separate, independent entities.
Sanara MedTech Inc. has agreed to a proposed business combination with MiMedx Group, Inc., aiming to create a leading regenerative medicine company focused on surgical and wound-care applications. The combination is described as bringing together complementary product portfolios and commercial capabilities.
The transaction is expected to close by the end of the year, subject to customary closing conditions, including required regulatory approvals and approval of Sanara stockholders. Until closing, Sanara and MiMedx will operate as separate companies and existing distributor agreements and day-to-day contacts at Sanara remain unchanged. Extensive forward-looking statements language highlights risks such as potential failure to obtain approvals, possible termination of the merger agreement, business disruption, transaction costs, and litigation or regulatory actions. A registration statement on Form S-4, including a proxy statement/prospectus, will be filed with the SEC, and investors are urged to read those materials when available.
Sanara MedTech Inc. has agreed to combine with MiMedx Group, Inc., a global provider of healing solutions for surgeries, wound care and burns. The companies state that the combination is intended to create a leading regenerative medicine business across multiple surgical subspecialties, leveraging MiMedx’s commercial capabilities with Sanara’s regenerative product portfolio.
The transaction is expected to close by the end of the year, subject to customary closing conditions, including regulatory approvals and approval by Sanara stockholders. Until closing, Sanara and MiMedx plan to operate as separate, independent companies with no changes to customers’ day‑to‑day contacts. A registration statement on Form S‑4, including a joint proxy statement/prospectus, is expected to be filed with the SEC, and investors are urged to review those materials when available.
Sanara MedTech Inc. describes its proposed business combination with MiMedx Group, Inc., a provider of healing solutions for surgeries, wound care and burns. The companies state that combining their complementary portfolios and commercial capabilities is intended to create a leading regenerative medicine company across multiple surgical subspecialties.
The transaction is expected to close by the end of the year, subject to customary closing conditions, including required regulatory approvals and approval of Sanara stockholders. Until closing, Sanara and MiMedx will continue to operate as independent companies and maintain normal manufacturing, patient programs and regulatory and customer engagement. The communication highlights extensive risk factors and notes that further details will be provided in an upcoming Form S-4 registration statement and proxy statement/prospectus to be filed with the SEC.
Sanara MedTech Inc. has entered into a definitive agreement to be acquired by MiMedx Group, Inc. in a cash and stock deal valuing Sanara at approximately $350 million. Sanara shareholders will receive $33.00 in cash plus 0.4735 shares of MiMedx common stock for each Sanara share, with the stock component’s value calculated using an average MiMedx share price of $4.22 over the five trading days through July 28, 2026. The merger consideration reflects a 46% premium to Sanara’s 30‑day volume weighted average share price as of that date. The transaction has been unanimously approved by both boards and is expected to close by year‑end, subject to Sanara shareholder approval, regulatory clearances and other customary closing conditions.
MiMedx Group plans to acquire Sanara MedTech for $35 per share, combining Sanara’s more than $100 million of surgical revenue with MiMedx’s soft-tissue surgical franchise. Management describes the deal as immediately accretive, adding products that expand MiMedx’s addressable surgical market by $4 billion and targeting at least $20 million in annual cost synergies.
For 2Q 2026, MiMedx reported $64 million in net sales, down sharply year over year after Medicare reimbursement cuts, but up 9% sequentially. Surgical revenue was $39 million, growing 15% year over year, while wound revenue was $25 million, down 61%. Adjusted gross margin was 74%, with adjusted EBITDA a loss of $8 million, narrowed from 1Q, and quarter-end net cash of $119 million.
Management expects wound volumes to continue stabilizing as patients migrate to wound care centers, where volumes grew double digits sequentially and annually. On a standalone basis, MiMedx reiterates 2026 guidance of $260–$290 million in net sales and adjusted EBITDA approaching breakeven. Assuming a 2026 close of the Sanara deal, leadership projects 2027 combined revenue well above $400 million and adjusted EBITDA margins of at least 20%, supported by a new $300 million six-year term loan at SOFR plus 6.25%.
MiMedx Group Inc. describes a planned acquisition of Sanara and explains that it expects to file a Form S-4 registration statement with the SEC. That filing will include a proxy statement for Sanara stockholders and a prospectus for MiMedx. The communication emphasizes that future SEC filings, including the definitive proxy statement/prospectus, will contain important information about the proposed transaction and will be made available for free through the SEC’s website and the investor relations sites of both companies.
The text also notes that directors and executive officers of MiMedx and Sanara may be considered participants in the proxy solicitation, with details about their interests described in each company’s 2026 annual meeting proxy statements and to be further detailed in the upcoming proxy statement/prospectus. It clarifies that this communication is not an offer to sell or buy securities, nor a solicitation of any vote or approval, and that any sale or issuance of securities will occur only in compliance with applicable securities laws.
Sanara MedTech and MiMedx Group have signed a definitive agreement for MiMedx to acquire Sanara, announced on July 29, 2026. The deal has not closed and remains subject to Sanara shareholder approval, regulatory clearances and other customary closing conditions, with closing targeted by the end of 2026.
Until closing, the companies will operate as separate, independent entities, with employees instructed to maintain existing roles, processes and reporting lines. Leadership, locations and workforce levels remain under evaluation through integration planning, and no specific personnel decisions or severance terms are committed at this stage.
MiMedx Group Inc. reports continued double-digit growth in its Surgical franchise and sequential improvement in Wound Care, and describes a positive business trajectory. The company has signed an agreement to acquire Sanara MedTech, aiming to create a larger regenerative medicine platform with a broader portfolio across acute and chronic wounds, burns, surgical tissue repair, and musculoskeletal applications.
The acquisition is expected to close by year end, subject to customary closing conditions and regulatory approval, and MiMedx and Sanara will operate separately until closing. MiMedx plans to file a registration statement on Form S-4 including a Sanara proxy statement and MiMedx prospectus, and investors are urged to read the registration statement and proxy statement/prospectus and related SEC filings when available.